<?xml version="1.0" encoding="UTF-8"?><Articles><Article><id>203</id><JournalTitle>CIRCUMSTANCES OF ONSET OF HEPATONEPHRITIS RELATED TO THE USE OF ARTEMISININ-BASED COMBINATION THERAPIES (ACTS)</JournalTitle><Abstract>The aim was to identify the main factors associated with unexpected serious cases of hepatonephritis related to
antimalarials and especially to artemesinin-based combination therapies (ACTs). This descriptive study included 113 cases of
hepatonephritis identified in the Ivorian pharmacovigilance database related to the use of antimalarials between 1 January
2007 and 30 July 2008. Out of the 273 medicines identified, antimalarials were the most involved (50.6%) especially
artemisinin-based combination therapies (ACTs) (58%). Antibiotics accounted for 13.6%, particularly fluoroquinolones (1 in
3) and traditional herbal medicine for 12.1%. In more than 70% of cases, therapeutic associations were identified as a matter
for misuse (43% of cases). On average, two drugs were associated including an antimalarial. The average duration of
treatment was 5.2 days; three treatment-sequences were performed with short times between the different sequences. Nonrecommended prescribing practices have promoted the onset of serious and unexpected side effects of artemisinin-based
combination therapies (ACTs).</Abstract><Email> kamadg@yahoo.fr</Email><articletype>Research</articletype><volume>9</volume><issue>1</issue><year>2019</year><keyword>Risk factors,Pharmacovigilance,Hepatotoxicity,Nephrotoxicity</keyword><AUTHORS>Jean-Claude Yavo,Mamadou KamagatÃ©,ThÃ©rÃ¨se Daubrey-Potey,Affoussiata Bakayoko,Henri DiÃ© Kakou</AUTHORS><afflication> Clinical Pharmacology Department of the Medical School of Abidjan. Felix Houphouet-Boigny University-Abidjan, Cote dâ€™Ivoire and the Technical Committee, Clinical Pharmacology Department of the Medical School of Abidjan. Alassane Ouattara University-Bouake, Cote dâ€™Ivoire and the Technical Committee, Clinical Pharmacology Department of the Medical School of Abidjan. Felix Houphouet-Boigny University-Abidjan, Cote dâ€™Ivoire and the Technical Committee, Clinical Pharmacology Department of the Medical School of Abidjan. Felix Houphouet-Boigny University-Abidjan, Cote dâ€™Ivoire and the Technical Committee,Clinical Pharmacology Department of the Medical School of Abidjan. Felix Houphouet-Boigny University-Abidjan, Cote dâ€™Ivoire and the Technical Committee.</afflication></Article></Articles>